Fig. 2
Development of PDXGEM for paclitaxel response prediction in breast cancer patient. a Volcano plot with log2 fold change of differential gene expressions (x-axis) in paclitaxel-sensitive and paclitaxel-resistant patient-derived xenograft (PDX) models and –log10P-value (y-axis). Black dots display the initial drug sensitivity probesets and red circles further indicate concordantly co-expressed biomarkers between the PDX models and breast cancer patients. b Clustering heatmap depicts correlation matrices of drug sensitivity genes in PDX models (left panel) and pretreatment cancer patients (right panel) before (top panel) and after (bottom panel) concordant co-expression. c The Pearson’s correlation coefficient between observed percent change in PDX tumor volumes (x-axis) and PDXGEM prediction scores for breast cancer PDX models (y-axis) was 0.982. d Receiver-operating characteristics curves of paclitaxel PDXGEM on seven different breast cancer data sets